Ceradyne reported decreased quarterly sales and earnings, with guidance projecting further declines in 2009 due to reduced body armor shipments. Despite efforts to offset this with growth in non-defense markets, uncertainties around key military contracts and delays from procurement protests create short-term challenges. This negative outlook and lowered guidance are likely to put downward pressure on the stock price in the near term.

[-1]